Antidepressant use has risen steadily for 30 years. Over 10% of adults in England now take them long-term, but evidence suggests up to half lack clear medical justification to continue. Patients and doctors are reluctant to stop treatment due to fears of relapse and withdrawal effects. Research indicates more proactive treatment review, slower drug tapering …
New research provides clarity on the most effective cessation aids available. Varenicline, cytisine, and e-cigarettes help the greatest proportion of people quit long-term. Slowly tapering nicotine dose before ending treatment may also boost success rates. Bupropion slightly raises the risk of serious side effects. Key Facts: Varenicline, cytisine, and e-cigarettes have the highest quit rates, …
Insomnia is a common sleep disorder affecting up to 15% of adults. While sedative medications are often prescribed, their long-term use can lead to dependence. As an alternative, antidepressants are widely used in clinical practice despite limited evidence supporting their efficacy and safety for insomnia. Key Facts: Insomnia affects up to 15% of adults, causing …
Depression is highly prevalent in older adults and those with cardiovascular disease. Selective serotonin reuptake inhibitors (SSRIs) are generally safe first-line treatments, but many wonder if they’re safe for those with cardiovascular disease. Key Facts: There is insufficient evidence to confirm the safety of most newer antidepressants for older and cardiovascular patients. SNRIs like venlafaxine …
Current antidepressants can take weeks to improve symptoms of depression. New research explores reasons for this delay and provides clues to develop more rapid-acting drugs. Key Facts: Most antidepressants increase brain serotonin and norepinephrine, but their mood benefits are delayed for weeks. Researchers are investigating other mechanisms that could explain this lag. Two leading theories …
Minor or subthreshold depression causes significant suffering and impairment, despite falling short of a major depression diagnosis. Effective early treatment is crucial to alleviate symptoms, improve functioning, and prevent progression to major depression. Both psychotherapy and antidepressants show efficacy, with antidepressants possibly having a slight advantage. In a shared decision-making model, patient preferences and values …
Zika virus (ZIKV) is a mosquito-borne flavivirus that has emerged as a significant global health threat, but there are currently no approved antiviral drugs for treating ZIKV infection. A new study identifies the SSRI drug dapoxetine as a promising antiviral candidate against ZIKV by targeting and inhibiting its RNA-dependent RNA polymerase. Key Facts: Dapoxetine was …
Depression often comes with significant sleep disturbances that can persist even after other symptoms improve. Choosing an antidepressant that alleviates sleep problems may improve outcomes. Key Facts: Sleep complaints like insomnia occur in 60-90% of depression patients. Poor sleep is associated with higher suicide risk. Sedative antidepressants like mirtazapine quickly improve sleep, while SSRIs/SNRIs may …
New research reveals that people with a history of methamphetamine dependence face a startling elevated risk of developing Parkinson’s disease or related movement disorders later in life. Key Facts: Individuals dependent on methamphetamine had almost 3 times the rate of Parkinson’s outcomes compared to matched controls from the general population. For women with methamphetamine dependence, the risk …
A new Mayo Clinic study is the first to clinically investigate whether antidepressants that impact mitochondrial function differently are associated with varying rates of treatment-emergent mania in bipolar disorder. The study found that antidepressants that increase mitochondrial energetics were associated with nearly double the rates of treatment-emergent mania compared to antidepressants that decrease mitochondrial energetics. …
